Considering the patient's current medications, which of the following is the most likely pharmacokinetic interaction that could affect their therapy?
Carbamazepine may enhance the metabolism of naproxen via UGT1A9, reducing its analgesic effect. Carbamazepine is a CYP3A4 inducer and may decrease the effectiveness of clonazepam. Naproxen's interaction with CYP2C9 could reduce its anti-inflammatory effects when taken with carbamazepine. Clonazepam may inhibit naproxen metabolism through CYP1A2, leading to increased side effects.